Clinical Trials for Ovarian Cancer

201407156

Neoadjuvant Chemotherapy Tumor Profiling in Ovarian Cancer: Genomic and Proteomic Analysis Phase N/A Principal Investigator Fuh, Katherine Disease Site Ovary

201804169

Cytokine-Induced Depression in Ovarian Cancer: Activation of Kynurenine Pathway Phase N/A Principal Investigator Kuroki, Lindsay Disease Site Corpus Uteri; Other Female Genital; Ovary; Soft Tissue

201806120

Ovation II: Protocol 201-17-201: A Phase I/II study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly…

201910142

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Phase III Principal Investigator Thaker, Premal Disease Site Other…

202001099

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Phase II Principal Investigator Mutch, David Disease Site Other Female Genital; Ovary; Soft Tissue Learn more about this study…

202002046

ENGOT-ov50 / INNOVATE-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Other…

202103080

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer Phase III (Cancer Control) Principal Investigator Thaker, Premal Disease Site Other Female Genital; Ovary;…

202103160

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Phase II (Cancer Control) Principal Investigator Thaker, Premal Disease Site Ovary;…

202106106

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in…